Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells.
about
PPARs and the cardiovascular systemBerberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injuryPPAR-gamma inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT(1)-ROS-MAPK signal pathway.Peroxisome proliferator-activated receptors in atherosclerosis and inflammation--an update.Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease.Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitroNovel insulin sensitizers: pharmacogenomic aspects.Vascular effects of GI262570X (PPAR-gamma agonist) in the brown adipose tissue of Han Wistar rats: a review of 1-month, 13-week, 27-week and 2-year oral toxicity studies.Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.PPARs and molecular mechanisms of transrepressionActivation of MEK 1/2 and p42/44 MAPK by angiotensin II in hepatocyte nucleus and their potentiation by ethanolAnti-proliferative effect of rosiglitazone on angiotensin II-induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway.PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.
P2860
Q24642728-11C79CD9-B9A0-445D-90FF-5E1FBB2CF150Q28576577-3B14094E-93CC-4F76-9D6B-5C500CA3D19EQ28578260-9CFFE5EE-509B-483B-9FB7-F5CF58B1FF1EQ34290152-A015018B-191F-4F55-B3D8-BA0B2674236BQ34290988-8464373F-8FE2-475E-85C2-3FE11D4886ADQ34342040-9CD7E84B-8C10-4F01-8C72-8AD0232492A1Q34576530-84CF00E0-FF14-4362-A9B9-80B78BB9F07FQ34609164-0459BF7F-A4DD-47B2-A171-D35BCB2DC3CBQ34790065-B5C079F1-A671-4115-9BBB-C6711F97366EQ35888976-E6C6AFF3-C374-4B21-96A9-DF6D99C41911Q36578665-0EC65E6C-CE4A-47EA-AE41-92C08223ED5AQ36791361-FEE79E3D-7139-438B-A51A-1C2B2EF148E9Q41815210-8132FDBC-577C-4515-BA44-8852418BEC91Q42725443-E874EAA3-83D5-4457-96D3-BDAD614ABB70Q46006542-CD882EB5-DD6E-41DE-A4AD-035DABEF843E
P2860
Troglitazone inhibits angiotensin II-induced extracellular signal-regulated kinase 1/2 nuclear translocation and activation in vascular smooth muscle cells.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Troglitazone inhibits angioten ...... vascular smooth muscle cells.
@en
type
label
Troglitazone inhibits angioten ...... vascular smooth muscle cells.
@en
prefLabel
Troglitazone inhibits angioten ...... vascular smooth muscle cells.
@en
P2093
P2860
P1433
P1476
Troglitazone inhibits angioten ...... vascular smooth muscle cells.
@en
P2093
P2860
P304
P356
10.1016/S0014-5793(99)00624-9
P407
P577
1999-06-01T00:00:00Z